Effectiveness of Bivalent mRNA COVID-19 Vaccines in Preventing SARS-CoV-2 Infection in Children and Adolescents Aged 5 to 17 Years

作者：Leora R. Feldstein, Amadea Britton, Lauren Grant, Ryan E. Wiegand, Jasmine Ruffin, Tara M Babu, Melissa Briggs Hagen, Jefferey L. Burgess, Alberto J. Caban‐Martinez, Helen Y. Chu, Katherine Ellingson, Janet A. Englund, Kurt T. Hegmann, Zuha Jeddy, Adam S. Lauring, Karen Lutrick, Emily T. Martin, Clare Mathenge, Jennifer K. Meece, Claire M. Midgley, Arnold S. Monto, Gabriella Newes‐Adeyi, Leah Odame‐Bamfo, Lauren E.W. Olsho, Andrew L. Phillips, Ramona P. Rai, Sharon Saydah, Ning Smith, Laura C. Steinhardt, Harmony L. Tyner, Meredith Vandermeer, Molly Vaughan, Sarang K. Yoon, Manjusha Gaglani, Allison L. Naleway · 发表于：JAMA · 年份：2024 · DOI：10.1001/jama.2023.27022 · 被引用次数：35 · 研究领域：SARS-CoV-2 and COVID-19 Research、Vaccine Coverage and Hesitancy、Immune responses and vaccinations

Importance: Bivalent mRNA COVID-19 vaccines were recommended in the US for children and adolescents aged 12 years or older on September 1, 2022, and for children aged 5 to 11 years on October 12, 2022; however, data demonstrating the effectiveness of bivalent COVID-19 vaccines are limited. Objective: To assess the effectiveness of bivalent COVID-19 vaccines against SARS-CoV-2 infection and symptomatic COVID-19 among children and adolescents. Design, Setting, and Participants: Data for the period September 4, 2022, to January 31, 2023, were combined from 3 prospective US cohort studies (6 sites total) and used to estimate COVID-19 vaccine effectiveness among children and adolescents aged 5 to 17 years. A total of 2959 participants completed periodic surveys (demographics, household characteristics, chronic medical conditions, and COVID-19 symptoms) and submitted weekly self-collected nasal swabs (irrespective of symptoms); participants submitted additional nasal swabs at the onset of any symptoms. Exposure: Vaccination status was captured from the periodic surveys and supplemented with data from state immunization information systems and electronic medical records. Main Outcome and Measures: Respiratory swabs were tested for the presence of the SARS-CoV-2 virus using reverse transcriptase-polymerase chain reaction. SARS-CoV-2 infection was defined as a positive test regardless of symptoms. Symptomatic COVID-19 was defined as a positive test and 2 or more COVID-19 symptoms with...